Sickle cell disease patients treated with NiCord® showed rapid engraftment and were cured of disease symptoms.
Jerusalem, Israel, Tuesday, December 6, 2016 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced results from its Phase 1/2 study of NiCord® for Sickle Cell Disease (SCD). The data were presented during a poster session at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, December 3-5, 2016 in San Diego, CA. [Read more…]